These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26312487)

  • 1. Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease.
    Kitatani K; Wada M; Perry D; Usui T; Sun Y; Obeid LM; Yaegashi N; Grabowski GA; Hannun YA
    PLoS One; 2015; 10(8):e0136633. PubMed ID: 26312487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.
    Vitner EB; Farfel-Becker T; Eilam R; Biton I; Futerman AH
    Brain; 2012 Jun; 135(Pt 6):1724-35. PubMed ID: 22566609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell lymphoma and myeloma in murine Gaucher's disease.
    Pavlova EV; Wang SZ; Archer J; Dekker N; Aerts JM; Karlsson S; Cox TM
    J Pathol; 2013 Sep; 231(1):88-97. PubMed ID: 23775597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaucher's disease.
    Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
    J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease.
    Watson L; Keatinge M; Gegg M; Bai Q; Sandulescu MC; Vardi A; Futerman AH; Schapira AHV; Burton EA; Bandmann O
    Neurobiol Dis; 2019 Jul; 127():563-569. PubMed ID: 30981829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Gba2 on neuronopathic Gaucher's disease and α-synuclein accumulation in medaka (Oryzias latipes).
    Nakanishi E; Uemura N; Akiyama H; Kinoshita M; Masanori S; Taruno Y; Yamakado H; Matsuzawa SI; Takeda S; Hirabayashi Y; Takahashi R
    Mol Brain; 2021 May; 14(1):80. PubMed ID: 33971917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minos-insertion mutant of the Drosophila GBA gene homologue showed abnormal phenotypes of climbing ability, sleep and life span with accumulation of hydroxy-glucocerebroside.
    Kawasaki H; Suzuki T; Ito K; Takahara T; Goto-Inoue N; Setou M; Sakata K; Ishida N
    Gene; 2017 May; 614():49-55. PubMed ID: 28286087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sucrose gradient analysis of phospholipid-activated beta-glucosidase in type 1 and type 2 Gaucher's disease.
    Garrett KO; Prence EM; Glew RH
    Arch Biochem Biophys; 1985 Apr; 238(1):344-52. PubMed ID: 3920967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rates of hydrolysis of N-oleoyl and N-stearoyl glucocerebroside in patients with Gaucher's disease.
    Peters SP; Aquino L; Naccarato WF; Gilbertson JR; Diven WF; Glew RH
    Biochim Biophys Acta; 1979 Oct; 575(1):27-36. PubMed ID: 508779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder.
    Christomanou H; Chabás A; Pámpols T; Guardiola A
    Klin Wochenschr; 1989 Oct; 67(19):999-1003. PubMed ID: 2615292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease.
    Tsuji S; Choudary PV; Martin BM; Stubblefield BK; Mayor JA; Barranger JA; Ginns EI
    N Engl J Med; 1987 Mar; 316(10):570-5. PubMed ID: 2880291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrastructural localization of glucocerebrosidase in cultured Gaucher's disease fibroblasts by immunocytochemistry.
    Willemsen R; van Dongen JM; Ginns EI; Sips HJ; Schram AW; Tager JM; Barranger JA; Reuser AJ
    J Neurol; 1987 Jan; 234(1):44-51. PubMed ID: 3819786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from glucosylceramide and Gaucher's disease.
    Luft FC
    J Mol Med (Berl); 1998 Oct; 76(11):723-4. PubMed ID: 9826117
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzymic differentiation of neurologic and nonneurologic forms of Gaucher's disease.
    Glew RH; Daniels LB; Clark LS; Hoyer SW
    J Neuropathol Exp Neurol; 1982 Nov; 41(6):630-41. PubMed ID: 6813430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of N-acyl phosphatidylethanolamines with different N-acyl groups as activators of glucocerebrosidase in various forms of Gaucher's disease.
    Basu A; Prence E; Garrett K; Glew RH; Ellingson JS
    Arch Biochem Biophys; 1985 Nov; 243(1):28-34. PubMed ID: 3933429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular basis of treatment in Gaucher's disease].
    Pocoví M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():32-8. PubMed ID: 22230123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I Gaucher's disease with homozygous R463C mutation without neurological involvement.
    Bolaman Z; Kadikoylu G; Levi E; Barutca S; Temucin K
    Haematologia (Budap); 2002; 32(4):487-93. PubMed ID: 12803123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher's disease in the presence of normal glucocerebrosidase activity.
    Schofield DE; Scott CR; Lage JM; Farrell DF
    Hum Pathol; 1992 May; 23(5):588-92. PubMed ID: 1568755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.
    Sun Y; Zhang W; Xu YH; Quinn B; Dasgupta N; Liou B; Setchell KD; Grabowski GA
    PLoS One; 2013; 8(3):e57560. PubMed ID: 23520473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation).
    Zimmer KP; le Coutre P; Aerts HM; Harzer K; Fukuda M; O'Brien JS; Naim HY
    J Pathol; 1999 Aug; 188(4):407-14. PubMed ID: 10440752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.